Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. Jobevne is a recombinant humanized monoclonal antibody used to treat several different types of cancer and is a biosimilar to the reference product Avastin® (bevacizumab). The approval of Jobevne expands Biocon Biologics’ biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). Biocon Biologics is a leading global player in biosimilars and insulin production and has achieved many 'firsts' in the industry. The approval of Jobevne is the seventh biosimilar approved in the U.S. and a strong addition to the company's robust oncology portfolio. It underscores the depth of the company's scientific expertise and commitment to expanding access to high-quality, affordable biologics.